Tamara Newcombe Sells 12,936 Shares of Ralliant (NYSE:RAL) Stock

Ralliant Corporation (NYSE:RAL) CEO Tamara Newcombe sold 12,936 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $71.79, for a total transaction of $928,675.44. Following the completion of the sale, the chief executive officer owned 251,967 shares of the company’s stock, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ralliant Trading Down 4.2%

Shares of Ralliant stock opened at $66.56 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00. The stock’s 50 day simple moving average is $69.02 and its 200-day simple moving average is $55.79. The stock has a market cap of $7.36 billion, a P/E ratio of -6.13, a P/E/G ratio of 2.58 and a beta of 1.60. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $75.41.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The firm had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Analysts predict that Ralliant Corporation will post 2.87 EPS for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be given a $0.05 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s payout ratio is currently -1.84%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on RAL shares. Royal Bank Of Canada increased their target price on shares of Ralliant from $71.00 to $73.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. Oppenheimer raised their target price on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Citigroup boosted their target price on Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Truist Financial restated a “buy” rating and issued a $82.00 price objective (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $75.70.

Hedge Funds Weigh In On Ralliant

Several institutional investors and hedge funds have recently added to or reduced their stakes in RAL. Danske Bank A S purchased a new position in shares of Ralliant during the 4th quarter worth approximately $25,000. Dunhill Financial LLC purchased a new stake in shares of Ralliant in the second quarter valued at approximately $25,000. Allworth Financial LP grew its holdings in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after acquiring an additional 293 shares during the period. Palisade Asset Management LLC acquired a new position in Ralliant during the third quarter worth $26,000. Finally, BOKF NA purchased a new position in Ralliant in the third quarter worth $29,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.